CeriBell’s (NASDAQ:CBLL) Quiet Period Set To Expire on November 20th

CeriBell’s (NASDAQ:CBLL) quiet period will expire on Wednesday, November 20th. CeriBell had issued 10,606,060 shares in its initial public offering on October 11th. The total size of the offering was $180,303,020 based on an initial share price of $17.00. During CeriBell’s quiet period, underwriters and any insiders that worked on the IPO are prevented from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Canaccord Genuity Group initiated coverage on CeriBell in a report on Tuesday, November 5th. They set a “buy” rating and a $30.00 price objective on the stock. William Blair initiated coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set an “outperform” rating for the company. TD Cowen started coverage on CeriBell in a report on Tuesday, November 5th. They set a “buy” rating and a $31.00 price target for the company. Bank of America assumed coverage on CeriBell in a research report on Tuesday, November 5th. They set a “buy” rating and a $32.00 price target on the stock. Finally, JPMorgan Chase & Co. began coverage on shares of CeriBell in a report on Tuesday, November 5th. They set an “overweight” rating and a $32.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, CeriBell has a consensus rating of “Buy” and an average price target of $31.20.

CeriBell Price Performance

Shares of CBLL opened at $27.55 on Friday. CeriBell has a 1-year low of $23.00 and a 1-year high of $29.53.

CeriBell (NASDAQ:CBLL) last announced its earnings results on Tuesday, November 12th. The company reported ($1.85) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($1.03). The firm had revenue of $17.20 million for the quarter, compared to analyst estimates of $17.06 million. On average, equities analysts predict that CeriBell will post -1.55 EPS for the current fiscal year.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.